SYDNEY, Australia – 20 May 2019 – The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 20 May 2019.
Dr. Eckstein recently joined Apollo Ventures as Managing Partner. Before that Dr. Eckstein was President of SR One Ltd., the corporate venture capital arm of GlaxoSmithKline which invests globally in emerging life science companies pursuing innovative science with significant impact on medical care and patients.
Imugene Executive Chairman, Paul Hopper said: “Imugene continues to attract a world class team. We welcome Dr Eckstein to the Board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”
Dr Eckstein currently serves on the boards of several biotechnology companies. He was co-founder and Director at Palleon Pharmaceuticals, and co-founder and Director at Decibel Therapeutics. He has served as a Director at ZappRx, Director at Gladius Pharmaceuticals, Chairman and Director at Thrasos Therapeutics, and Director at Alios Biopharma (acquired by Johnson & Johnson).
Dr Eckstein has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies. He is a Kaufman Fellow, founder of Action Potential Venture Capital (APVC) and created OneStart, the world’s largest life science accelerator. He was a General Partner at the trans-Atlantic venture capital firm TVM Capital.
Dr Eckstein holds several issued patents and has authored a number of scientific publications. He earned his Doctorate, summa cum laude, in Biological Chemistry in at the University of Konstanz and Harvard University.
Subject to shareholder approval, the Company agrees to issue 25 million unlisted options exercisable at A$0.04 (5 mil options), A$0.042 (10 mil options) and A$0.045 (10 mil options) per option expiring 3 years from the date of approval to be vested over 24 months to Dr. Jens Eckstein.
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Find out more at www.imugene.com.
Issued for and on behalf of Imugene by Instinctif Partners.
For more information please contact: firstname.lastname@example.org